Health-Related Quality of Life in Molecular Targeted Therapy
Quality of life (QOL) in medicine has been evaluated as health-related QOL (HRQOL). HRQOL is a component of patient-reported outcomes (PROs). HRQOL is a true clinical endpoint when validated and reliable QOL instruments are used. Clinical trials often evaluated HRQOL as the secondary endpoint. Improvement of progression-free survival (PFS) with improved HRQOL would be clinically meaningful outcome. Recently, several randomized trials have been conducted with QOL as the primary endpoint. A randomized trial of early palliative care (EPC) integrated with standard oncologic care or standard oncologic care alone in patients with metastatic non-small cell lung cancer (NSCLC) showed that EPC significantly improved QOL and mood. Median overall survival (OS) was longer among patients receiving EPC. The data suggests that QOL is highly related to OS and QOL evaluation should be integrated into oncology practice for patients with advanced lung cancer. To improve patient management, effective communication is necessary. Communication skill training (CST) program based on SHARE protocol is effective for both oncologists and patients with cancer. Because physicians tend to concentrate on cancer-related outcomes and often neglect assessments of QOL, tools to evaluate QOL would be useful to improve quality of care in patients with advanced lung cancer.
KeywordsQuality of life (QOL) Health-related quality of life (HRQOL) Patient-reported outcomes (PROs) Early palliative care (EPC) Communication skill training (CST)
- 3.Ohe Y, Ohashi Y, Kubota K et al (2007) Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 18:317–323CrossRefPubMedGoogle Scholar
- 4.Okamoto I, Yoshioka H, Morita S et al (2010) Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study. J Clin Oncol 28:5240–5246CrossRefPubMedGoogle Scholar
- 9.Galetta D, Cinieri S, Pisconti S et al (2015) Cisplatin/pemetrexed followed by maintenance pemetrexed versus carboplatin/paclitaxel/bevacizumab followed by maintenance bevacizumab in advanced nonsquamous lung cancer: the GOIM (Gruppo Oncologico Italia Meridionale) ERACLE Phase III randomized trial. Clin Lung Cancer 16:262–273CrossRefPubMedGoogle Scholar
- 14.DeVita VT Jr, Lawrence TS, Rosenberg SA (2011) DeVita, Hellman, and Rosenberg’s cancer: principles and practice of oncology, 9th edn. Wolters Kluwer Health/Lippincott Williams & Wilkins, PhiladelphiaGoogle Scholar